RXI-762

N/A

Report date: 2022/07/01 15:29:28

NME

Base Information

Drug NameRXI-762

Drug Alias NameRXI-762

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionBromodomain-containing protein 4 inhibitorsProgrammed cell death protein 1 blockersT cell immunoglobulin and ITIM domains inhibitors

TargetsT cell immunoglobulin and ITIM domainsBromodomain-containing protein 4Programmed cell death protein 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPhio Pharmaceuticals Corp

China Registration ClassN/A

Develop Information

Active CompaniesPhio Pharmaceuticals Corp

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A